Small-molecule inhibitors at the PSD-95/nNOS interface attenuate MPP+-induced neuronal injury through Sirt3 mediated inhibition of mitochondrial dysfunction

Neurochemistry International

Volumn 79, Issue , 2014, Pages 57-64

  Hu, Wei ^a,b   Guan, Lai Shun ^b   Dang, Xing Bo ^b   Ren, Peng Yu ^b   Zhang, Yue Lin ^b  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Mitochondrial dysfunction; nNOS; Parkinson's disease; PSD 95; Sirt3

Indexed keywords

ANTIPARKINSON AGENT; CALCIUM; CASPASE 3; CYTOCHROME C; IC87201; LACTATE DEHYDROGENASE; NEURONAL NITRIC OXIDE SYNTHASE; NEUROPROTECTIVE AGENT; POSTSYNAPTIC DENSITY PROTEIN 95; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SIRTUIN 3; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ZL006; 2-((1H-BENZO(D)(1,2,3)TRIAZOL-5-YLAMINO)METHYL)-4,6-DICHLOROPHENOL; CHLOROPHENOL; DLGH4 PROTEIN, RAT; MEMBRANE PROTEIN; MOLECULAR LIBRARY; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; SIGNAL PEPTIDE; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BRAIN CELL CULTURE; BRAIN MITOCHONDRION; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CALCIUM TRANSPORT; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; EMBRYO; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION SWELLING; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; DRUG EFFECTS; GENE SILENCING; METABOLISM; MITOCHONDRION; MOLECULAR LIBRARY; MPTP POISONING; NERVE CELL; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; CALCIUM; CELLS, CULTURED; CHLOROPHENOLS; GENE KNOCKDOWN TECHNIQUES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MEMBRANE PROTEINS; MITOCHONDRIA; MPTP POISONING; NEURONS; NEUROPROTECTIVE AGENTS; NITRIC OXIDE SYNTHASE TYPE I; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; RNA, SMALL INTERFERING; SIRTUIN 3; SMALL MOLECULE LIBRARIES; TRIAZOLES;

EID: 84909972262     PISSN: 01970186     EISSN: 18729754     Source Type: Journal    
DOI: 10.1016/j.neuint.2014.10.005     Document Type: Article

References (51)

1. Aarts M., Liu Y., Liu L., Besshoh S., Arundine M., and Gurd J.W. Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions Science 298 2002 846 850
2. Aarts M.M., and Tymianski M. Novel treatment of excitotoxicity: targeted disruption of intracellular signalling from glutamate receptors Biochem. Pharmacol 66 2003 877 886
3. Ahmed I., Bose S.K., Pavese N., Ramlackhansingh A., Turkheimer F., and Hotton G. Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias Brain 134 2011 979 986
4. Ahn B.H., Kim H.S., Song S., Lee I.H., Liu J., and Vassilopoulos A. A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis Proc. Natl. Acad. Sci. U.S.A. 105 2008 14447 14452
5. Bell E.L., Emerling B.M., Ricoult S.J., and Guarente L. SirT3 suppresses hypoxia inducible factor 1alpha and tumor growth by inhibiting mitochondrial ROS production Oncogene 30 2011 2986 2996
6. Bellizzi D., Rose G., Cavalcante P., Covello G., Dato S., and De Rango F. A novel VNTR enhancer within the SIRT3 gene, a human homologue of SIR2, is associated with survival at oldest ages Genomics 85 2005 258 263
7. Calon F., Morissette M., Ghribi O., Goulet M., Grondin R., and Blanchet P.J. Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment Prog. Neuropsychopharmacol. Biol. Psychiatry 26 2002 127 138
8. Cao J., Viholainen J.I., Dart C., Warwick H.K., Leyland M.L., and Courtney M.J. The PSD95-nNOS interface: a target for inhibition of excitotoxic p38 stress-activated protein kinase activation and cell death J. Cell Biol 168 2005 117 126
9. Chen T., Cao L., Dong W., Luo P., Liu W., and Qu Y. Protective effects of mGluR5 positive modulators against traumatic neuronal injury through PKC-dependent activation of MEK/ERK pathway Neurochem. Res 37 2012 983 990
10. Chen T., Fei F., Jiang X.F., Zhang L., Qu Y., and Huo K. Down-regulation of Homer1b/c attenuates glutamate-mediated excitotoxicity through endoplasmic reticulum and mitochondria pathways in rat cortical neurons Free Radic. Biol. Med 52 2012 208 217
11. Chen T., Zhang L., Qu Y., Huo K., Jiang X., and Fei Z. The selective mGluR5 agonist CHPG protects against traumatic brain injury in vitro and in vivo via ERK and Akt pathway Int. J. Mol. Med 29 2012 630 636
12. Chen T., Yang Y.F., Luo P., Liu W., Dai S.H., and Zheng X.R. Homer1 knockdown protects dopamine neurons through regulating calcium homeostasis in an in vitro model of Parkinson's disease Cell. Signal 25 2013 2863 2870
13. Chen T., Zhu J., Zhang C., Huo K., Fei Z., and Jiang X.F. Protective effects of SKF-96365, a non-specific inhibitor of SOCE, against MPP+-induced cytotoxicity in PC12 cells: potential role of Homer1 PLoS ONE 8 2013 e55601
14. Crosby N., Deane K.H., and Clarke C.E. Amantadine in Parkinson's disease Cochrane Database Syst. Rev 1 2003 CD003468
15. Crosby N.J., Deane K.H., and Clarke C.E. Amantadine for dyskinesia in Parkinson's disease Cochrane Database Syst. Rev 2 2003 CD003467
16. Dai S.H., Chen T., Wang Y.H., Zhu J., Luo P., and Rao W. Sirt3 attenuates hydrogen peroxide-induced oxidative stress through the preservation of mitochondrial function in HT22 cells Int. J. Mol. Med 34 2014 1159 1168
17. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models Neuron 39 2003 889 909
18. Del Dotto P., Pavese N., Gambaccini G., Bernardini S., Metman L.V., and Chase T.N. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study Mov. Disord 16 2001 515 520
19. Dexter D.T., and Jenner P. Parkinson disease: from pathology to molecular disease mechanisms Free Radic. Biol. Med 62 2013 132 144
20. Diguet E., Gross C.E., Bezard E., Tison F., Stefanova N., and Wenning G.K. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment Neurology 62 2004 158 author reply 158-159
21. Estornell E., Fato R., Pallotti F., and Lenaz G. Assay conditions for the mitochondrial NADH:coenzyme Q oxidoreductase FEBS Lett 332 1993 127 131
22. Exner N., Lutz A.K., Haass C., and Winklhofer K.F. Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences EMBO J. 31 2012 3038 3062
23. Florio S.K., Loh C., Huang S.M., Iwamaye A.E., Kitto K.F., and Fowler K.W. Disruption of nNOS-PSD95 protein-protein interaction inhibits acute thermal hyperalgesia and chronic mechanical allodynia in rodents Br. J. Pharmacol 158 2009 494 506
24. Haigis M.C., and Sinclair D.A. Mammalian sirtuins: biological insights and disease relevance Annu. Rev. Pathol 5 2010 253 295
25. Hallett P.J., and Standaert D.G. Rationale for and use of NMDA receptor antagonists in Parkinson's disease Pharmacol. Ther 102 2004 155 174
26. Hauser D.N., and Hastings T.G. Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism Neurobiol. Dis 51 2013 35 42
27. Kennedy M.B. The postsynaptic density at glutamatergic synapses Trends Neurosci 20 1997 264 268
28. Kim E., Naisbitt S., Hsueh Y.P., Rao A., Rothschild A., and Craig A.M. GKAP, a novel synaptic protein that interacts with the guanylate kinase-like domain of the PSD-95/SAP90 family of channel clustering molecules J. Cell Biol 136 1997 669 678
29. Kim S.H., Lu H.F., and Alano C.C. Neuronal Sirt3 protects against excitotoxic injury in mouse cortical neuron culture PLoS ONE 6 2011 e14731
30. Mandemakers W., Morais V.A., and De Strooper B. A cell biological perspective on mitochondrial dysfunction in Parkinson disease and other neurodegenerative diseases J. Cell Sci 120 2007 1707 1716
31. Marino M.J., Valenti O., and Conn P.J. Glutamate receptors and Parkinson's disease: opportunities for intervention Drugs Aging 20 2003 377 397
32. Martinez T.N., and Greenamyre J.T. Toxin models of mitochondrial dysfunction in Parkinson's disease Antioxid. Redox Signal 16 2012 920 934
33. Michan S., and Sinclair D. Sirtuins in mammals: insights into their biological function Biochem. J. 404 2007 1 13
34. Nash J.E., and Brotchie J.M. Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat Mov. Disord 17 2002 455 466
35. Onyango P., Celic I., McCaffery J.M., Boeke J.D., and Feinberg A.P. SIRT3, a human SIR2 homologue, is an NAD-dependent deacetylase localized to mitochondria Proc. Natl. Acad. Sci. U.S.A. 99 2002 13653 13658
36. Parone P.A., Da Cruz S., Han J.S., McAlonis-Downes M., Vetto A.P., and Lee S.K. Enhancing mitochondrial calcium buffering capacity reduces aggregation of misfolded SOD1 and motor neuron cell death without extending survival in mouse models of inherited amyotrophic lateral sclerosis J. Neurosci 33 2013 4657 4671
37. Petralia R.S. Distribution of extrasynaptic NMDA receptors on neurons ScientificWorldJournal 2012 2012 267120
38. Pickrell A.M., Pinto M., and Moraes C.T. Mouse models of Parkinson's disease associated with mitochondrial dysfunction Mol. Cell. Neurosci 55 2013 87 94
39. Qiu X., Brown K., Hirschey M.D., Verdin E., and Chen D. Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation Cell Metab 12 2010 662 667
40. Qiu X., Brown K.V., Moran Y., and Chen D. Sirtuin regulation in calorie restriction Biochim. Biophys. Acta 1804 2010 1576 1583
41. Ravina B.M., Fagan S.C., Hart R.G., Hovinga C.A., Murphy D.D., and Dawson T.M. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment Neurology 60 2003 1234 1240
42. Sala C., Piech V., Wilson N.R., Passafaro M., Liu G., and Sheng M. Regulation of dendritic spine morphology and synaptic function by Shank and Homer Neuron 31 2001 115 130
43. Sattler R., Xiong Z., Lu W.Y., Hafner M., MacDonald J.F., and Tymianski M. Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein Science 284 1999 1845 1848
44. Schapira A.H. Mitochondria in the aetiology and pathogenesis of Parkinson's disease Lancet Neurol 7 2008 97 109
45. Schulz J.B. Mechanisms of neurodegeneration in idiopathic Parkinson's disease Parkinsonism Relat. Disord 13 Suppl. 3 2007 S306 S308
46. Sheng M. The postsynaptic NMDA-receptor-PSD-95 signaling complex in excitatory synapses of the brain J. Cell Sci 114 2001 1251
47. Sundaresan N.R., Gupta M., Kim G., Rajamohan S.B., Isbatan A., and Gupta M.P. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice J. Clin. Invest 119 2009 2758 2771
48. Szalai G., Krishnamurthy R., and Hajnoczky G. Apoptosis driven by IP(3)-linked mitochondrial calcium signals EMBO J. 18 1999 6349 6361
49. Yu Z., Liu N., Li Y., Xu J., and Wang X. Neuroglobin overexpression inhibits oxygen-glucose deprivation-induced mitochondrial permeability transition pore opening in primary cultured mouse cortical neurons Neurobiol. Dis 56 2013 95 103
50. Zhou L., Li F., Xu H.B., Luo C.X., Wu H.Y., and Zhu M.M. Treatment of cerebral ischemia by disrupting ischemia-induced interaction of nNOS with PSD-95 Nat. Med 16 2010 1439 1443
51. Parkinson Study Group A multicenter randomized controlled trial of remacemide hydrochloride as monotherapy for PD Neurology 54 2000 1583 1588